Form 4 for RPRX Royalty Pharma plc
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-10 · accession 0001209191-22-056677 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2022-11-14 | 2022-11-10 | RPRX | Lloyd George W. | EVP, CLO, Investments | S - Sale | $43.85 | -50.0K | 355.0K | -12% | -$2.19M |
| D | 2022-11-14 | 2022-08-12 | RPRX | Lloyd George W. | EVP, CLO, Investments | G - Gift | $0.00 | -5,889 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2022-11-10 | S | D | 25,000 | $43.85 | 165,000 | I By GWL 2020 G, LLC | — | — | (F1) Class A Ordinary Shares sold pursuant to a 10b5-1 plan. (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Class A Ordinary Shares | 2022-11-10 | S | D | 25,000 | $43.85 | 355,000 | I By GWL 2014 G, LLC | — | — | (F1) Class A Ordinary Shares sold pursuant to a 10b5-1 plan. (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.65 to $43.94 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | LP interests in RPI US Partners 2019, LP | 2022-08-12 | G | D | 5,889 | $0.00 | 0 | D | — · — to — | 58,890 Class A Ordinary Shares | (F4) No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. (F6) Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. |